GSK said it now expects adjusted operating profit to increase between 13-15% for the year after it reported a rise in net profit in the third quarter, mainly due to the U.S. launch of its Arexvy vaccine.
This copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order multiple copies, please contact Dow Jones Reprints at 1-800-843-0008 or visit www.djreprints.com.
https://www.wsj.com/business/earnings/gsk-plc-raises-guidance-after-rsv-vaccine-lifts-earnings-ca7bd091GSK PLC raised its guidance after third-quarter net profit rose mainly due to the U.S. launch of its Arexvy vaccine, although it missed analysts’ forecasts. The British pharmaceutical giant said Wednesday that net profit from continuing operations for the third quarter was 1.46 billion pounds , boosted by the vaccine for respiratory syncytial virus, or RSV, compared with GBP759 million a year earlier and a company-compiled consensus of GBP1.87 billion.This copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
GSK raises annual forecasts again on strong Arexvy launchGSK (GSK.L) raised its full-year profit and sales forecasts on Wednesday for the second time this year, betting on the strong launch of its respiratory syncytial virus (RSV) vaccine and steady demand for its shingles shot.
Read more »
Italy's Iveco Group raises FY guidance again after strong Q3Italy's Iveco Group raises FY guidance again after strong Q3
Read more »
Amgen’s stock jumps premarket after earnings beat and company again raises guidanceCiara Linnane is MarketWatch's investing- and corporate-news editor. She is based in New York.
Read more »
GSK signs $1 billion deal for exclusive license to J&J's hepatitis B therapyGSK signs $1 billion deal for exclusive license to J&J's hepatitis B therapy
Read more »
Pfizer RSV vaccine lags GSK’s as head-to-head competition underwayPfizer RSV vaccine lags GSK’s as head-to-head competition underway
Read more »
Drug Stocks Keep Falling on Earnings. It Could Be a Long Week.Companies scheduled to report their results include Pfizer, GSK, Eli Lilly, and Novo Nordisk.
Read more »